Pyrrolo [1,2-b] [1,2,5]benzothiadiazepine 5,5-dioxides (PBTDs) induced apoptosis in human BCR-ABLexpressing leukemia cells. The apoptotic activity was also observed in primary leukemic blasts, obtained from chronic myelogenous leukemia (CML) patients at onset or from patients in blast crisis and who were imatinib-resistant. Compounds 5 and 14 induced apoptosis before BCR-ABL protein expression and tyrosin phosphorylation were affected and activated different caspases in the apoptotic pathway. PBTDs are a new class of valid candidates for the treatment of CML.
Chronic myelogenous leukemia (CML) is a clonal disease of hemopoietic progenitor cells. 1 CML is characterized by the expression of the BCR-ABL fusion gene, which is derived from the fusion of the cellular breakpoint cluster region (BCR) gene and the Abelson murine leukemia oncogene (ABL). 2 BCR-ABLtransformed cells activate multiple signal transduction pathways responsible for increasing proliferation. The BCR-ABL protein also activates downstream survival pathways 3 that collectively provide BCR-ABL cells with a survival advantage over the normal cells, thereby contributing to the leukemic phenotype 4 and conferring higher resistance against conventional cytotoxic drugs. 5 Imatinib (IM, imatinib mesilate, STI-571, Gleevec) (1) is now the first-choice drug for all newly diagnosed CML patients 6 (Chart 1). IM is a potent inhibitor in all of the ABL tyrosine kinases, including BCR-ABL. There is a lot of evidence that the oncogene BCR-ABL would protect growth-factor-dependent hemopoietic cells from apoptosis. According to this role, inhibition of BCR-ABL expression by IM showed restoration of susceptibility to apoptosis and enhancement of cell death. 7 Exposure to IM alone induced apoptosis in HL-60/BCR-ABL and K562 cells. 8 Despite its initial efficacy, IM selects drug resistance due to the emergence of mutation at the kinase domain and overexpression of BCR-ABL. 9 To overcome resistance, some strategies have been adopted, such as dose escalation and synergistic combination with conventional drugs (cytarabine, homoharringtonine, IFN), alternative ABL inhibitors, or BCR-ABL protein down-regulating agents. 7 The antitumor activity of pyrrolo[2,1-c] [1, 4] benzodiazepines (PBDs) related to anthramycin (2) was extensively studied by our research group, as it is well documented in Thurston's excellent review. 10 A correlation between antitumor activity and apoptosis was well demonstrated. It was hypothesized that anthramycin, like other DNA-alkylating agents, would induce apoptosis through a mythocondrial pathway. 11 In addition, in the past few years the activity of some PBDs (i.e., 3) 12 in leukemia cell lines, such as K562 and Jurkat cells, was reported.
Our extensive studies on anti-AIDS agents led to the discovery of pyrrolo [1,2-b] [1,2,5]benzothiadiazepine 5,5-dioxides (PBTDs) as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. 13 Given the high structural similarity between PBTDs and PBDs, we selected two PBTDs (5 and 14) for a preliminary screening aimed to discover new proapoptotic and antileukemia agents. In fact, to our knowledge the anti-CML properties of PBTDs have not been investigated until now.
In our first experiments, PBTDs 5 and 14 induced apoptosis in K562 cells (Table 1 ). In addition, they efficiently induced cell death in BCR-ABL-positive leukemia cells taken from patients who were at onset or were IM-resistant (Tables 2 and  3) . These results prompted us to conduct apoptotic mechanism studies on PBTDs 5 and 14. At the same time we planned the synthesis of new PBTD derivatives to investigate the effect of (i) substituents at the 10-aroyl group, (ii) a 1-naphthoyl group at position 10, and (iii) the introduction of a methylene spacer group at position 11. Our findings indicate that the PBTDs are a new class of potential agents for the treatment of CML.
Chemistry
Aroylation of the ester 14 with aroyl chlorides in boiling 1-bromo-3-chloropropane in the presence of sodium hydrogen carbonate afforded the corresponding amides 4-8 (Scheme 1). The starting ester 14 was prepared by treatment of 19 14 with ethyl 2,2-diethoxyacetate in the presence of 4-toluenesulfonic acid (PTSA) as a catalyst in boiling absolute ethanol via a Pictet-Spengler type reaction. 15 Derivatives 9-13 were prepared by aroylation of 15 in boiling dioxane in the presence of triisobutylamine. The starting acetate 15 was obtained by reaction of 19 with ethyl 3,3-diethoxypropionate in aqueous glacial acetic acid at 100°C. Lithium hydroxide hydrolysis of the esters 14 and 15 afforded the corresponding acids 16 and 17. Lithium aluminum hydride-aluminum chloride reduction of acid 14 gave alcohol 18. The racemic mixtures 5 and 14 were separated using analytical and semipreparative enantioselective HPLC to give enantiomers 20 and 21, and 22 and 23, respectively, with >98.0% ee and in 80-90% yield.
Apoptotic Activity in K562 Cells
The characteristic morphological features of apoptosis, such as cytoplasmic vacuolization, patterns of chromatin condensation and micronuclei, and negligible necrosis, were observed upon treatment of the cells with tested compounds. The chromatin appeared clumped and was observed at the nuclear periphery. The samples showed micronuclei or the nuclear body surrounded by a double membrane and cytoplasmic vacuolization. Large plasmalemmal blebbing was visible in the cells incubated with Figure 1, left (×18 000) ), whereas such morphological changes did not appear in the control cells (Figure 1, right) .
(
The apoptotic activity of 5 and 14 in K562 cells was timedependent at 5, 10, and 15 µM ( Figure 1S in Supporting Information). At 10 µM, 4-15 showed high apoptotic activity at every time point. A preliminary structure-activity relationship (SAR) inspection indicated that the apoptotic activity of 4-13 was weakly affected by the aroyl substitutents at position 10 of the PBTD nucleus or by the methylene linker at position 11 (compare carboxylates 4-8 and acetates 9-13). Compounds 14 and 15 deprived of the 10-aroyl portion also showed potent apoptotic activity with greater difference after 8 h (compare 4-13 with 14 and 15). Replacement of the ester 14 with the alcohol 18 caused a neat decrease of apoptotic activity. Free acids 16 and 17 did not show the morphological features of apoptosis, showing an apoptotic activity that was comparable to that of control cells. We hypothesized that these compounds would not be able to penetrate the K562 cell membrane and to activate the cellular mechanisms. To evaluate the influence of the chiral center at position 11 of the PBTD ring, the racemates 5 and 14 were separated by chiral HPLC. Both (+)-(S)-enantiomers 21 and 23 and the corresponding (-)-(R)-counterparts 22 and 24 showed slight differences of activity in the range 3-5% (Table 1S in Supporting Information).
Apoptotic Activity in Bone Marrow and Peripheral Blood Cells from CML Patients
We harvested bone marrow and peripheral blood cells from 12 consecutive CML patients at onset. We also harvested peripheral blood cells from 2 patients in blast crisis evolved under IM treatment. Cell samples were cultured in vitro, treated with 5 or 14 for 24 and 48 h, and then subjected to DNA fragmentation assay. Tested PBTDs induced apoptosis in all of the samples, including those from the two patients in blast crisis and who were IM-resistant (Tables 2 and 3 ). The typical appareance of endonucleosome DNA after treatment with 5, 6, or 14 in patients cases 1, 11, and 14 is shown in Figure 2S in Supporting Information.
Caspase Activation Activity in K562 Cells
We analyzed the activated apoptotic pathways by performing Western blot analyses of caspase-8 and -9 proforms. Upon drug treatment caspase-8 and -9 became activated in most apoptotic models in receptor-activated caspase-8 and -3 pathways or in cytochrome c release-dependent caspase-9 and -3 pathways.
In both pathways, caspase-3 activation is the final event of the caspase cascade. After 24 h, 14 significantly reduced the procaspase-8 immunoreactive band without changing the procaspase-9 intensity. On the other hand, lysates from 5-treated K562 cells showed no evidence of alteration in procaspase-8 concentration and paralleled a dramatic decrease of procaspase-9 expression levels. Compound 14 seemed to activate the direct extrinsic caspase-8 mediated pathway, resulting in faster proteolysis induction.
In contrast, 5 seemed to induce apoptosis through the mitochondrial intrinsic pathway with a relatively delayed proteolytic effect ( Figure 3S in Supporting Information).
Compounds 5 and 14 Induced Apoptosis by Bypassing the Apoptotic Suppressor BCR-ABL
Western blot analyses of BCR-ABL and tyrosine phosphorylated proteins at different intervals showed that some downregulation of the BCR-ABL immunoreactive band was detected only after 16 h upon treatment with 14 and after 24 h upon treatment with 5. One point worth noting was that at regular intervals we noticed a slight diminution of ABL and actin proteins. At the same time, no significant early change in the pattern of tyrosine phosphorylated proteins was detected (at least not until the same BCR-ABL protein level started to fade). This confirmed that no inhibition of a putative BCR-ABL-mediated major phosphorylative process was induced within the cell. These observations suggested that down-regulation of BCR-ABL is not involved in the early events associated with PTDBinduced apoptosis. Accordingly, both 5 and 14 induced apoptosis before the levels of BCR-ABL protein expression and its tyrosin phosphorylation were affected. Both actin protein degradation and whole-cell phosphorylation pattern changes (caused by widespread proteolysis) were dependent on the apoptotic process rather than the inactivation of BCR-ABL kinase ( Figure 4S in Supporting Information).
In conclusion, our preliminary results demonstrated that PBTDs 4-15 induced apoptosis in human BCR-ABL-expressing leukemia cells. The apoptotic activity was also observed in primary leukemia blasts, obtained from CML patients at onset or from patients in blast crisis and who were IM-resistant. Apoptotic mechanism studies conducted on PBTDs 5 and 14 showed that they activated the caspase activity through two different pathways. These compounds also induced apoptosis before the BCR-ABL protein expression and tyrosine phosphorylation levels were affected. These findings suggest that PBTDs are endowed with powerful growth inhibition on leukemia cells.
Besides the high activity displayed by some PBTDs discovered in the present preliminary work, we are aware that further results are obtainable to evaluate the chemotherapeutic potential of this novel class of anti-CML agents. For this reason, the synthesis of new PBTD derivatives is now ongoing in our laboratories as part of more in-depth structure-activity relationship (SAR) studies guided by molecular modeling.
Experimental Section
Chemistry. Melting points (mp) were determined on a Büchi 510 apparatus and are uncorrected. Infrared spectra (IR) were run on a SpectrumOne FT spectrophotometer. Band position and absorption ranges are given in cm -1 . Proton nuclear magnetic resonance ( 1 H NMR) spectra were recorded on Bruker 200 and 400 MHz FT spectrometers in the indicated solvent. Chemical shifts are expressed in δ units (ppm) from tetramethylsilane. Column chromatography was performed on columns packed with alumina from Merck (70-230 mesh) or with silica gel from Merck (70-230 mesh). Aluminum oxide TLC cards from Fluka (aluminum oxide precoated aluminum cards with fluorescent indicator at 254 nm) and silica gel TLC cards from Fluka (silica gel precoated aluminum cards with fluorescent indicator at 254 nm) were used for thin-layer chromatography (TLC). Elemental analysis results were found within (0.4% of the theoretical values. (()-10,11-Dihydro-10-benzoylpyrrolo[1,2-b]-[1,2 ,5]benzothiadiazepine-11-carboxylate 5,5-Dioxide (4). A mixture of 14 (1.00 g, 0.0033 mol), benzoyl chloride (0.48 g, 0.0034 mol), NaHCO 3 (0.31 g, 0.0037 mol), and 1-bromo-3-chloropropane (50 mL) was refluxed overnight. After cooling, the mixture was filtered and the solvent evaporated. The residue was purified by column chromatography (silica gel, chloroform). Yield 40%, mp 172-180°C (ethanol). 1 000 92 mol) in THF (10 mL) was added and the mixture was stirred at room temperature for 3 h. After cooling at 0°C, the reaction mixture was quenched with 4 N sodium hydroxide and extracted with dichloromethane. The organic layer was separated, washed with brine, and dried. Removal of the solvent gave crude 19, which was passed through a chromatographic column (silica gel, chloroform). Yield 87%, mp 136-138°C (ethanol) (lit. 13 
mp 135-136°C).
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